PARP inhibitor era: current status and future directions

被引：2
|
作者：
Coleman, Robert L. [1 ,2 ,3 ]
机构：
[1] Texas Oncol, Gynecol Oncol, The Woodlands, TX USA
[2] Sarah Cannon Res Inst SCRI, The Woodlands, TX USA
[3] Sarah Cannon Res Inst SCRI, Nashville, TN 37203 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / 04期
关键词：
Ovarian Cancer; BEVACIZUMAB;
D O I：
10.1136/ijgc-2023-004464
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：444 / 445
页数：2
相关论文
共 50 条
  • [1] PARP Inhibitors in Breast Cancer: Current Status and Future Directions
    Isakoff, Steven J.
    ONCOLOGIST, 2017, 22 : S3 - S3
  • [2] Assessment practices in the era of managed care: Current status and future directions
    Piotrowski, C
    JOURNAL OF CLINICAL PSYCHOLOGY, 1999, 55 (07) : 787 - 796
  • [3] Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
    Jiang, Xuan
    Li, Weihua
    Li, Xiaoying
    Bai, Huimin
    Zhang, Zhenyu
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4371 - 4390
  • [4] CURRENT STATUS - FUTURE DIRECTIONS
    MATTHEWS, JL
    CALCIFIED TISSUE RESEARCH, 1978, : 425 - 429
  • [5] Bevacizumab - current status and future directions
    Midgley, R
    Kerr, D
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 999 - 1004
  • [6] Current status and future directions of The Annals
    Nahata, MC
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (02) : 321 - 322
  • [7] Colletotrichum - current status and future directions
    Cannon, P. F.
    Damm, U.
    Johnston, P. R.
    Weir, B. S.
    STUDIES IN MYCOLOGY, 2012, (73) : 181 - 213
  • [8] Vasculitis: Current status and future directions
    Youinou, Pierre
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2008, 35 (1-2) : 1 - 4
  • [9] Vasculitis: Current Status and Future Directions
    Pierre Youinou
    Clinical Reviews in Allergy & Immunology, 2008, 35 : 1 - 4
  • [10] Schizotaxia: Current status and future directions
    Ming T. Tsuang
    William S. Stone
    Franziska Gamma
    Stephen V. Faraone
    Current Psychiatry Reports, 2003, 5 (2) : 128 - 134
12345